Novavax’s money is going in the wrong direction

_Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox._ Hello, all. Damian here with an update on the plight of the 

_other_ Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom. THE NEED-TO-KNOW THIS MORNING * Ocular Therapeutics announced a shakeup of its

senior management team and a $325 million private placement. * Amylyx Therapeutics said results from a closely followed Phase 3 study of its treatment for ALS could come before the start of

the second quarter — earlier than previously expected. * Moderna earnings are here. NOVAVAX’S MONEY IS GOING IN THE WRONG DIRECTION The good news for Novavax is that it’s no longer facing a

$700 million dispute with a global charity organization. The bad news is that settling that dispute will force the struggling company to pay out $400 million over the next five years. STAT+

Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS.

Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe